Cargando…
Profile of atacicept and its potential in the treatment of systemic lupus erythematosus
The importance of B cell activating factors in the generation of autoantibodies in patients with systemic lupus erythematosus (SLE) is now recognized. The two key factors, known as BAFF and APRIL, produced by a variety of cells including monocytes, dendritic cells and T cells, also help to regulate...
Autores principales: | Cogollo, Estafania, Silva, Marta Amaral, Isenberg, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357613/ https://www.ncbi.nlm.nih.gov/pubmed/25834391 http://dx.doi.org/10.2147/DDDT.S71276 |
Ejemplares similares
-
Profile of atacicept and its potential in the treatment of systemic lupus erythematosus [Corrigendum]
Publicado: (2015) -
Effects of atacicept on disease activity in patients with moderate to severe systemic lupus erythematosus: APRIL-SLE randomized trial
por: Isenberg, David, et al.
Publicado: (2014) -
Population pharmacokinetics of atacicept in systemic lupus erythematosus: An analysis of three clinical trials
por: Pitsiu, Maria, et al.
Publicado: (2023) -
Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
por: Isenberg, David, et al.
Publicado: (2015) -
Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme
por: Gordon, Caroline, et al.
Publicado: (2019)